U.s. fda approves expanded indication for vonvendi® [von willebrand factor (recombinant)] for adults and children with von willebrand disease

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the u.s. food and drug administration (fda) has approved the supplemental biologics license application (sbla) for vonvendi® [von willebrand factor (recombinant)], expanding the indication to include routine prophylaxis to reduce the frequency of bleeding episodes in adults with von willebrand disease (vwd), including those with type 1 and 2 disease, and on-demand and perioperative management of bl.
TAK Ratings Summary
TAK Quant Ranking